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Despite medical advancements, the development of  an ideal vascular prosthesis 
still poses a great challenge. In this study the researchers tried to test and verify the 
characteristics of  a new type of  vascular prosthesis, using adiponectin (Adipograft 
Ra 1vk 7/350) developed at the Knitting Research Institute, a.s. Brno. Two types of  
vascular prostheses (12 with adiponectin and 6 as a control without adiponectin) were 
implanted in nine healthy 4-year-old Merino sheep. The implantation site was the 
common carotid artery and the length of  the implant was 10 cm. We applied the theory 
of  the protected coagulum, whereby all sheep received antibiotics as a prophylactic 
measure. A Doppler U.S. was performed before fi nishing each operation, in order to 
verify the patency of  the prostheses. Each animal was followed up during the whole 
study and the prostheses were extirpated on days 30 and 100 (1 and 3 months). It was 
observed that all prostheses coated with adiponectin showed patency after extirpation. 
The lumen implants were of  a consistent thickness of  7 mm. Histological study of  the 
implanted prostheses confi rmed a quick, high quality, healing. Experimental vascular 
prostheses coated with adiponectin appeared to be successful in clinical practice. 
The researchers think that Adipograft Ra 1vk 7/350 can be a turning point in the 
development of  vascular prostheses, due to its patency and quick healing.
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INTRODUCTION
The aim of  this experimental animal study was to evaluate, test and verify the 
characteristics of  a new type of  vascular prosthesis using adiponectin (Adipograft 
Ra 1vk 7/350). Adiponectin is a hormone produced by the white adipose tissue and 
is released directly into the blood, where its levels are within the range 0.5-30 μg/mL 
with a total concentration of  0.01% of  the total plasma proteins [1]. It belongs to the 
same group of  adipokines as leptin, TNF-α, plasminogen activator inhibitor, adipsin 
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and resistin [2]. It is a collagen-like protein, which shows similarities with collagen type 
VIII and X [1].
It is up-regulated by insulin and an insulin-like growth factor; it is down-regulated 
by obesity and increased secretion of  TNF-α. Adiponectin acts directly on skeletal 
muscles and liver, infl uencing the total concentration of  triglycerides. This causes the 
activation of  receptors and kinase enzymes, which thereby activate β-oxidation and 
gluconeogenesis. As a result, there is a decrease in the total triglycerides level in the 
cells and an increase in their sensitivity to insulin [3].
The total level of  adiponectin is at a lower level in diabetes mellitus type 2 and 
atherosclerotic subjects. Obesity and high BMI decrease the synthesis of  adiponectin, 
as well. Low levels of  adiponectin increase LDL-cholesterol levels in the blood, which 
are then transformed by monocytes into foam-cells, which develop atherosclerotic 
plaques, which thereby damage the vascular endothelium [3]. We have to bear in mind 
that atherosclerosis is an infl ammatory process caused by foam-cell accumulation in 
the damaged endothelium. [4].
Atherosclerosis was found in patients with low levels of  adiponectin in the blood 
vessels. This caused a reduced ability of  the damaged endothelium to repair, and 
increased the possibility for the formation of  atherosclerotic plaques [5].
The accumulated adiponectin in the blood vessel intima, infl uences the adhesion 
of  expression molecules, such as: VCAM-1 and ICAM-1; and TNF-α. This thereby 
affects the adhesion of  monocytes and reduces LDL- microphages uptake and the 
formation of  foam-cells [3].
Another property of  adiponectin is its ability to reduce the formation of  smooth 
muscle cells in the injured blood vessel wall. This prevents extreme muscle formation 
and concomitant narrowing of  the lumen. This was for the fi rst time described in 
adiponectin defi cient rats [5].
The usual adiponectin level in obese patients is approximately 3.7 μg/mL, while in 
healthy patients it is around 8.9 μg/mL. [4,6]. Adiponectin plasma concentration 
correlates with HDL and cholesterol levels. The positive association is presumably 
due to the adiponectin’s ability to activate the enzyme lipoprotein lipase [4,6].
The characteristics of  adiponectin, which give it a quality of  an endothelium protector 
against atherosclerosis and neovascularisation, are used for the development of  
a vascular prosthesis coated with this hormone. The adiponectin coating on the 
inner surface of  the vascular prosthesis reduces the formation of  the thrombocyte 
adhesion factor (TNF-α) and decreases the formation of  smooth muscle cells, thereby 
preventing narrowing of  the lumen [5].
It also supports the migration and proliferation of  endothelial cells, leading to a 
faster formation of  the neointima, which aids the inhibition of  blood clotting in the 
inner surface of  the knitted prosthesis. A quick and intact endothelial layer formation 
prevents the precipitation of  platelets and thereby prevents thrombus formation.
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It is now possible to manufacture adiponectin, by means of  DNA recombination, 
in the form of  human or rat adiponectin. E. Coli is employed in its production. The 
market price of  recombinant adiponectin is approximately US$200 for 25 μg.
An important aim, when developing vascular prostheses, is to maximize the period 
of  lumen patency and, at the same time, to increase their functionality and long-term 
stability. The lumen of  the prosthesis must be as smooth as possible, in order to 
improve patency, while the outer layer surface should be rough, in order to aid healing 
[7]. In order to avoid thrombosis the fl ow inside the prosthesis must be laminar, and 
not turbulent [8,9].





Adiponectin’s characteristics, of  protecting the endothelium against atherosclerosis 
and neovascularisation, were utilized in the development of  a prosthesis coated with 
this hormone. Adiponectin, in certain amounts on the inner site of  the prosthesis, 
accelerates healing.
Adipograft Ra 1vk 7/350® vascular prostheses were subjected to biocompatibility 
tests and they complied with the following requirements: non-toxicity; non-antigenic 
and non-carcinogenic properties; exhibiting permanent inertness. Tests for possible 
haemolytic effects, cytotoxicity and pyrogenicity were performed with satisfactory 
results [10].
Other tests of  biocompatibility - such as allergisation, irritability, systemic toxicity, 
subchronic toxicity, and genotoxicity - were performed with the RaK vascular 
prosthesis with collagen, which has been manufactured for several years in accordance 
to the approval No 89/0313/00-IIB of  SUKL (State Institute for Drug Control).
MATERIALS AND METHODS
Nine healthy Merinolandschaf, aged about 4 years and free of  infectious diseases, were 
used as experimental animals [11]. The sheep weight was between 76 and 97 kg (mean= 
85.55; median = 81; mode = 78 and 81). They were all subjected to biochemical and 
hematological laboratory tests:
• Total protein, albumin, glucose, creatinine, urea, total bilirubin, aspartate amino 
transferase and gamma glutamyl transferase activities, Na, K, Ca, Cl, and Mg levels.
• Complete blood count and differential count of  leukocytes.
• Thrombin, prothrombin time and fi brinogen coagulation blood test.
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After the clinical tests were done, the sheep were moved to the experimental 
department of  the Clinic for Ruminant Diseases, at the University of  Veterinary 
and Pharmaceutical Sciences Brno, for quarantine, to enable their adaptation and to 
control their health conditions on a daily basis [12]. The above mentioned clinical tests 
were performed also before the removal of  the prosthesis. Examination of  the results 
confi rmed that the experimental animals were healthy and the selected parameters 
were within the normal range.
Animals were fed with meadow hay, ad libitum, augmented with a corn and vitamin-
mineral mixture.
In this study, 12 vascular prostheses with adiponectin and 6 control prostheses without 
adiponectin (commonly used in clinical practice) were implanted and subsequently 
removed in the following way:
First month (day 29, 34 and 35), 6 prostheses with adiponectin;
Third month (day 99, 99, 98, 99, 98, 93), 6 prostheses with adiponectin and 6 controls.
Antibiotics (Amoxicillin) were administered before surgery as a prophylactic, in 
accordance with the protected coagulum method. The antibiotics were continued for 
three days.
All sheep were fasted for 8 hours and were not allowed to drink for the 2 hours before 
anesthesia. The animals were premedicated with fl unixin/meglumine 1.1 mg/kg/i.v. 
(Mefl osyl, Fort Dodge Snímal Veterinaria), detomidin 0.02 mg/Kg/i.m. (Domosedan, 
Pfi zer), midazolam 0.2 mg/kg/i.v. (Dormicum, Roche). An 18G intravenous catheter 
(Vasofi x, B.Braun) was inserted into the v. saphena with subsequent complete anesthesia 
with a bolus of  ketamine 5mg/kg/i.v. (Narketan, Vetoquinol). To facilitate intubation, 
propofol was slowly administered (Propofol 1 %, Fresenius Kabi) at a dose of  0.5-
1 mg/kg until effect (diminished gag refl ex and complete loss of  jaw muscles tonus). 
Thereon, the sheep were intubated with a 11 mm endotracheal cannula. Once they 
were intubated, they were positioned in dorsal recumbence and connected to an 
inhalation device. General anesthesia was maintained using isofl urane (Aeran, Barter) 
with ETISO 1.2-1.4 volume percent. During anesthesia, sheep were ventilated using 
CMV with a tidal volume of  6-10 ml/kg, PEEP up to 5 cm H2O, and PIP up to 
20 cm H2O. Vital functions were monitored (Datex S/5, Datex-Ohmeda). Continuous 
infusions of  crystalloid solutions (Ringer’s solution, Barter’s solution), at 10 ml/kg 
per hour, were administered perioperatively. Mean arterial pressure was maintained 
at above 75 mm Hg. To prevent the pressure from decreasing below this value, a 
continuous infusion of  dobutamine (1-3 micrograms/kg/min) was administered. The 
length of  time from anesthesia to complete recovery did not exceed 60 minutes in any 
of  the treated animals. The anesthesiology protocols for prosthesis implantation and 
extirpation were identical.
After wiping the dorsally recumbent animal with disposable drapes, surgical exposure of  
the tissue was performed to the right and left sides in front of  the sternocleidomastoid 
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muscle from a longitudinal incision above the trachea. The common carotid artery 
was carefully surgically exposed. Attention was focused on the separation from the 
nerve plexus, with special attention to the n.vagus. After intravenous administration 
of  heparin (about 10000 IU, according to the animal’s weight), the carotid artery was 
closed with vascular clamps. A segment of  about 10 cm of  length of  the right and left 
common carotid artery was replaced by the studied prosthesis.
All implanted vascular prostheses had a length of  10 cm and the implant lumen was 
always constant (7 mm). Since the 1950s it has been established that the length of  the 
implant has to be at least 5.5-6 cm. Otherwise tissue integration does not occur, as 
tissue integration is mainly the result of  growth of  cellular structures from the stump 
of  the host’s artery [13, 14].
Suture material Prolene 6-0 with a 13 mm needle (W 8706) was used. A continuous 
suture was performed. Edges of  at least 2 mm were cut, both from the prosthesis and 
from the artery. End-to-end anastomoses were performed (Figure 1). After suturing 
the prostheses and careful hemeostasis, the platysma muscle and skin were sutured. 
Upon completion of  the prosthesis suture, heparin was not neutralized with protamine 
sulphate and anticoagulation therapy was not administered after the operation.
When the surgical procedure was fi nished and the inhalation device was disconnected, 
sheep were moved to a post-surgery box and positioned sternally. Extubation was 
performed at the moment the swallowing refl ex was recovered. Thereafter the sheep 
were continuously observed until complete recovery and restoration of  all refl exes. 
Postoperatively, they were administered the analgesic fl unixin/meglumine (Mefl osyl, 
Fort Dodge Laboratories) in a dose of  1.1 mg/kg i.v. for three days.
The average anesthesia time for prosthesis implantation / explantation was 120+/- 24 
minutes. The average surgical time for the implantation of  the prosthesis was between 
85 and 120 minutes, whereas for explantation the required time was between 60 
and 120 minutes. Animals were followed up on a daily basis by a professional staff  
(veterinarians, veterinary technicians and keepers). When there were complications, 
head researchers were contacted to solve them.
A Doppler ultrasound examination was performed to verify the patency of  each 
implanted prosthesis post-operatively and at monthly intervals (Figure 2). 
In the experiment, tissue integration of  the vascular prosthesis-implant was tested in 
the arterial system of  sheep at an early time period (30 days) and a late one (100 days). 
In each case, the explanted prosthesis was analyzed macroscopically (Figures 3 and 4) 
and microscopically (Figures 5 to 8).
The animals were not sacrifi ced as from earlier experiments conducted by the fi rst 
author on moufl ons and other sheep breeds, one can assume that the absence of  the 
carotid bed is not a life threatening condition for these animals.
The study was approved by the Ethical Committee of  the University of  Veterinary 
and Pharmaceutical Sciences Brno and followed all protocols according to law. In 
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addition, all persons included in this experimental assessment were licensed for animal 
manipulation in experimental medicine, according to paragraph 17, article 1, of  the 
Law 246/1992 Sb. for animal protection against tyranny.
Figure 1. Bilateral vascular prostheses implantation – Sheep 1. Figure 2. Bilateral Doppler 
of  RCCA and LCCA – 99 days after implantation – Sheep 1. Figure 3. Macroscopic view 
of  implanted vascular prosthesis without adiponectin (Control group / LCCA) – Sheep 1. 
Figure 4. Macroscopic view of  the implanted vascular prosthesis with adiponectin / RCCA 
– Sheep 1. Figure 5. Microscopic (histological) transverse view of  the implanted prosthesis 
with adiponectin. Hematoxylin-Eosin.  40 X – Sheep 1. Figure 6. Microscopic (histological) 
longitudinal view of  the implanted prosthesis with adiponectin. Hematoxylin – Eosin.  40 X 
– Sheep 1.
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RESULTS
Results are presented as follows:
Table 1 shows the operation protocol, the number of  days with the implanted vascular 
prosthesis, and its patency.
All vascular prostheses implanted with and without adiponectin remained patent until 
the day of  extirpation (see Figures 3 and 4). However, the vascular prostheses with 
adiponectin presented a faster and better healing. This was ascertained by histological 
methods (see Figures 5 to 8).
Figures 3 and 4 show the macroscopic view of  the prostheses with and without 
adiponectin, in Merinolandschaf  / Württemberger sheep number 1 (identifi cation tag 
18238, weight 94 kg, aged 4 years).
The histological descriptions of  the vascular prostheses, with and without adiponectin, 
were as follows:
Figure 5 shows a microscopic view of   a prosthesis with adiponectin, with a 
pseudointima formation throughout the entire (100%) lumen circumference. Having 
a thickness of  714 μm and being partly epithelized, it corresponds to the late phase.
Figure 6 is a longitudinal view of  the prosthesis with adiponectin, presenting a 
transversal cut of  the anastomosis with adequate fi brous graft incorporation.
Figure 7 shows a microscopic view of  the control prosthesis without adiponectin, 
with a pseudointima formation in just 50% of  the lumen that is partly endothelised 
and 748 μm thick.
In the rest of  the lumen, there is a mural thrombus with a thickness of  382 μm. It 
corresponds to the organizational part of  the late phase.
Figure 7. Microscopic (histological) transversely view of  the implanted prosthesis without 
adiponectin (Control group). Hematoxylin – Eosin. 40 X – Sheep 1. Figure 8.  Microscopic 
(histological) longitudinal view of  the implanted prosthesis without adiponectin (Control 
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Figure 8 is a longitudinal view of  the control prosthesis without adiponectin, presenting 
a transversal cut of  the anastomosis with a satisfactory fi brous graft incorporation. 
The here described neointima is 677 μm thick.
Some parts of  all prostheses exhibit a well-developed external fi brous coating and 
properly formed fi bers of  refractive heterogeneous material with focal minor chronic 
infl ammatory cellularity and scattered giant multinuclear cells around the fi bers. In 
the pores of  the prosthesis, there is a mature, well-vascularised granulation tissue 
with infrequent chronic infl ammatory cells. There are also histiocytes and isolated 
neutrophils. The internal coating of  the lumen (pseudointima) is formed by a relatively 
cellular connective tissue of  a maximum thickness of  0.7 mm with fi broblasts and 
infrequent lymphocytes. Circumferentially, the pseudointima is endothelised. This 
corresponds to the late phase of  graft incorporation. Within the artery-to-prosthesis 
transition, fi brous tissue integration with good graft incorporation was identifi ed.
DISCUSSION
Before humans are subjected to clinical trials in relation to the development of  a new 
vascular prosthesis it is necessary to assess rheological and immunological reactions to 
the prosthesis in a living animal, in vivo. It is still not possible to replace such experiments 
with in vitro methods. Therefore, it is still important to use animals in clinical trials.
Findings are of  a relative value and there is still no guarantee they would be fully 
applicable to humans. Functionality of  the vascular prosthesis can be deduced with 
great certainty, but the quality and speed of  tissue integration cannot be completely 
evaluated, as cellular and extracellular activities differ in various animal species. 
Nevertheless it is evident that animal experiments preliminarily exclude inconvenient 
and incorrect technical procedures and sub-standard prosthetic implants.
The animals that were chosen to be the subject of  the experiment were sheep, because 
of  the following similarities of  their carotid arteries with humans:
• Behavior of  the arterial bed;
• Carotid length and accessibility;
• Endothelisation at anastomosis site.
Another advantage is that sheep require minimum care in the postoperative period and 
the follow- up is not too expensive [15].
Our results proved that vascular prostheses, coated on their inner surface with 
adiponectin, exhibited reduced thrombogenicity and improved patency, when 
compared with prostheses with no adiponectin. The researchers observed that none 
of  the control vascular prostheses (without adiponectin), that are normally used in 




Histological results indicated a decreased formation of  smooth muscle cells, thereby 
preventing narrowing of  the lumen. It was clear that, in the case of  the prosthesis 
coated with adiponectin, there was a better migration and proliferation of  endothelial 
cells. Thus there was a faster and intact (100%) endothelial layer formation around the 
prosthesis lumen, preventing platelet aggregation and so preventing the formation of  
a thrombus.
The researchers found that vascular prostheses coated with adiponectin improve 
the rheologic characteristics for healing. Evaluation was based on functionality, 
macroscopic and microscopic fi ndings.
The differences in the time needed for the surgery depend on the surgeons’ technique 
and skills. No perioperative and post-operative complications were observed.
In view of  the fact that the experimental sample was very small, the results obtained 
cannot be taken as representative, but they do indicate that further research should be 
conducted into the fi eld of  vascular prosthesis for human use.
The results obtained indicated that vascular prostheses coated with adiponectin 
exhibited very good properties, i.e. no obliteration and quick healing, compared with 
those without it. Adiponectin has defi nite benefi cial effects on vascular prosthesis 
patency. As this remains a promising vascular prosthesis, there is an incentive to do 
more research in order to go to step 2 clinical trials which will entail trials on humans.
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EKSPERIMENTALNA PROCENA NOVOG TIPA VASKULARNE 
PROTEZE SA ADIPONEKTINOM (ADIPOGRAFT Ra 1vk7/350) 
KOD OVACA
PODLAHA Jiří, SCHWANHAEUSER Kräuff
Uprkos napretku medicine, razvoj idealne vaskularne proteze predstavlja značajan iza-
zov. U ovoj studiji, obavljeno je testiranje i verifi kacija karakteristika novog tipa vasku-
larne prosteze upotrebom adiponektina (Adipograft Ra 1vk 7/350) koji je razvijen 
u Knitting istraživačkom institutu u Brnu. Dva tipa vaskularnih prosteza (12 sa adi-
ponektinom i 6 kontrolnih, bez adiponektina) su implantirane u devet zdravih ovaca 
starih 4 godine, rase Merino. Implant, dužine 10 cm je implantiran u zajedničku karot-
idnu arteriju. Primenjena je teorija zaštićenog koaguluma pri čemu su ovce profi laktički 
primile antibiotsku terapiju. Pre završetka svake operacije, obavljen je Doppler U.S. 
u cilju verifi kacije prohodnosti prosteze. Svaka je životinja posmatrana tokom celog 
trajanja studije, a prosteze su uklanjane 30. i 100. dana (posle jednog i posle tri mes-
eca). Uočeno je da su sve prosteze koje su sadržavale adiponektin posle uklanjanja 
pokazivale prohodnost. Celokupnom dužinom, lumen implanta je bio veličine do 7 
mm. Histološkim ispitivanjem implantiranih prosteza, ustanovljeno je brzo i veoma 
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kvalitetno zarastanje. Eksperimentalni rezultati ukazuju da su vaskularne prosteze 
obavijene adiponektinom uspešne sa stanovišta kliničke prakse. Na osnovu rezultata 
prohodnosti i brzine zarastanja, može da se zaključi da Adipograft Ra 1vk 7/350 može 
da predstavlja revoluciju u razvoju vaskularnih prosteza.
